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Purpose: Social anxiety disorder (SAD) is a disabling condition that affects almost 5% of the 
general population. Many types of drugs have shown their efficacy in the treatment of SAD. 
There are also some data regarding psychotherapies, but no data are available today about the 
efficacy of brain stimulation techniques. The aim of the study is to compare the efficacy of 
noninvasive brain stimulation neuro psycho physical optimization (NPPO) protocol performed 
by radio electric asymmetric conveyor (REAC) with that of sertraline in adults with SAD.
Patients and methods: Twenty SAD patients on sertraline were compared with 23 SAD 
patients who refused any drug treatment and who chose to be treated with NPPO-REAC brain 
stimulation. This was a 6-month, open-label, naturalistic study. Patients on sertraline received 
flexible doses, whereas NPPO-REAC patients received two 18-session cycles of treatment. 
  Clinical Global Improvement scale items “much improved” or “very much improved” and 
Liebowitz Social Anxiety Scale total score variation on fear and avoidance components were 
used to detect the results. The statistical analysis was performed with t-test. All measures ,0.05 
have been considered statistically significant.
Results: Ten of 23 subjects on NPPO-REAC and six of the 20 taking sertraline were much 
improved or very much improved 1 month after the first NPPO-REAC cycle (t1). Sixteen of the 
subjects on NPPO-REAC and ten of the subjects taking sertraline were much improved or very 
much improved 1 month after the second NPPO-REAC cycle (t2). In respect of the Liebowitz 
Social Anxiety Scale, at t1 NPPO-REAC resulted in statistically more efficacy for sertraline on 
both fear and avoidance total scores. At t2, NPPO-REAC resulted in statistically more efficacy 
for sertraline on fear but not on avoidance.
Conclusion: NPPO-REAC is an effective treatment for SAD, allowing substantial and clinically 
meaningful reductions in symptoms and disability in comparison with sertraline.
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Introduction
Social anxiety disorder (SAD), also known as social phobia, is characterized by the 
marked fear of being observed or evaluated by others,1–3 in particular nonrelatives. 
In such situations, patients with SAD fear that they will say or do something to 
embarrass or humiliate themselves or that others will notice that they are anxious. 
Consequently, subjects with SAD often avoid situations2,4,5 where such scrutiny might 
take place, or they endure them with intense distress.6 This can result in impaired 
functioning and   disrupted quality of life.7,8 Patients affected from SAD may have 
few social   relationships, experience trouble dating, drop out of school9,10 or work,11 
reject promotions at work, become demoralized, abuse alcohol,12–16 and develop 
other psychiatric disorders17–19 like major depression.20–22 SAD is more frequent in Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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the primary care setting,23–27 but it is often undiagnosed28 
and, consequently, untreated. This low rate of recognition 
and appropriate treatment reflects the fact that social phobia 
remains a largely neglected anxiety disorder.29.30 However, 
the available epidemiological studies31–33 show a prevalence 
of at least 5% in the general population.
Most clinicians associate the term “social phobia” with a 
fear of public speaking. Indeed, social phobia often involves 
public speaking and, in some cases, does so exclusively. 
However, there is a variant of SAD that is more pervasive 
and usually more disabling: generalized SAD7, 34–37 (gSAD). 
Subjects with gSAD typically fear and avoid a broad array 
of situations that most people take for granted, such as 
speaking in small groups, attending social gatherings, talk-
ing to people in authority, and interacting with peers in an 
informal setting.
The neglect of gSAD obviously extends into the area of 
treatment. Treatment options for gSAD include monoamine 
oxidase inhibitors,38 reversible inhibitors of monoamine 
oxidase A (moclobemide),39,40 and, in particular, selective 
serotonin reuptake inhibitors.41–43 Based on their success in 
the treatment of many mood and other anxiety disorders, 
selective serotonin reuptake inhibitors have been investigated 
in the treatment of social phobia, and they are considered as 
first-choice drugs for the treatment of gSAD. Excluding some 
psychotherapies,44–47 at the moment, no data are available 
about other therapeutical approaches such as noninvasive 
brain stimulation techniques like radio electric asymmet-
ric conveyor (REAC) treatments. Neuro psycho physical 
optimization (NPPO)-REAC has demonstrated efficacy in 
improving certain psychiatric disorders such as stress-related 
disorders,48–53 anxiety,53,54 depression,53–55 bipolar disorder,56 
and behavioral and psychiatric symptoms in Alzheimer 
  disease.57 The main goal of the present study was to investi-
gate the efficacy of NPPO-REAC in the treatment of gSAD 
in patients who refuse drug treatment.
Materials and methods
This was an open-label, naturalistic study. Patients with 
gSAD came spontaneously to our medical centers and were 
observed in the normal clinical practice. gSAD was diag-
nosed with structured clinical interview58,59 according to 
the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition, Text Revised.
The data for the current study were collected from the 
Psychic Studies Center, Cagliari, Italy, for 20 patients 
(Table 1) treated with flexible doses of sertraline60–62 (mean 
dose 125.0 ± 15.5 mg/day once a day) and from the Rinaldi 
Fontani Institute, Florence, Italy, for 23 patients (Table 1) 
who refused drug treatment and were treated with two cycles 
of 18 NPPO-REAC sessions. The time between the two 
treatment cycles was about 3 months. None of the patients 
enrolled in the study had been previously treated for gSAD, 
and none took psychotropic drugs during the study, except 
for sertraline. Patients were evaluated for safety and efficacy 
about 1 month after the end of the first NPPO-REAC treat-
ment cycle (t1) and about 1 month after the end of the second 
NPPO-REAC treatment cycle (t2). According to the Rinaldi-
Fontani protocol, this time period lasted about 6 months and 
determined the duration of the comparison study. The main 
efficacy variables were the percentage of responders at t1 and 
t2, defined as those rated on the Clinical Global Improve-
ment (CGI)63,64 scale as 1 (very much improved) or 2 (much 
improved), and the mean change from baseline at t1 and t2 on 
the Liebowitz Social Anxiety Scale65–67 (LSAS) total score. 
The LSAS is a 24-item assessment of fear and avoidance of 
several public-social situations. Statistical analysis of the 
obtained data was performed using t-test, and P , 0.05 was 
considered statistically significant.
radio electric asymmetric conveyer
The REAC68,69 is a medical device that is based on an innova-
tive technology for biostimulation and/or bioenhancement 
techniques. The model used in this study (Convogliatore di 
Radianza Modulante, ASMED, Florence, Italy) is specific 
for noninvasive brain stimulation techniques.
The NPPO-REAC treatment protocol consisted of seven 
radiofrequency bursts of 500 ms each at a frequency of 10.5 
GHz and a specific absorption rate of 7 µW/kg, applied 
by touching the metallic tip of the REAC probe to the ear 
pavilion.
Results
Both treatments were well tolerated, and no patients suspended 
the study because of any side effects. At baseline, in both the 
NPPO-REAC and sertraline groups, for fear and avoidance, 
a marked clinical picture was detected (Figures 1 and 2).
Ten (43.5%) of 23 subjects on NPPO-REAC and six 
(30.0%) of the 20 taking sertraline were much improved or 
Table 1 Demographics
Treatment Patients Male Female Mean age (years)
nPPO-reAc 23 8 15 31.4 ± 2.3
sertraline 20 5 15 30.7 ± 2.8
Abbreviations: nPPO, neuro psycho physical optimization; reAc, radio electric 
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very much improved 1 month after the first NPPO-REAC 
cycle (t1) (Table 2). Sixteen (69.6%) of the subjects on NPPO-
REAC and ten (50.0%) of the subjects taking sertraline were 
much improved or very much improved 1 month after the 
second NPPO-REAC cycle (t2) (Table 2). The   proportion 
of NPPO-REAC responders (ie, a CGI score of 1 or 2) was 
significantly greater than for sertraline (Table 2).
At t1, for NPPO-REAC, LSAS total fear score decreased 
from 64.4 ± 2.4 to 48.0 ± 2.7 (Figure 1) and for sertraline 
from 60.7 ± 3.2 to 57.1 ± 1.9 (t-test t = −12.595, DF = 41, 
P = 0.000) (Figure 1); for NPPO-REAC, LSAS total avoid-
ance score decreased from 67.2 ± 4.3 to 50.0 ± 3.2 and for 
sertraline from 62.4 ± 2.7 to 54.2 ± 2.3 (t-test t = −4.873, 
DF = 41, P = 0.000) (Figure 2).
From baseline to t1, gSAD improved from marked to 
moderate both for fear (Figure 1) and for avoidance (Figure 2) 
in the NPPO-REAC treatment group, and only for avoidance 
in the sertraline group.
At t2, for NPPO-REAC, LSAS total fear score decreased 
from 48.0 ± 2.7 to 32.4 ± 3.4 (Figure 1) and for sertraline from 
57.1 ± 1.9 to 34.4 ± 2.4 (t-test t = −2.196, DF = 41, P , 0.05) 
(Figure 1); for NPPO-REAC, LSAS total avoidance score 
decreased from 50.0 ± 3.2 to 30.5 ± 2.9 (Figure 2) and for 
sertraline from 54.2 ± 2.3 to 32.0 ± 2.2 (t-test t = −1.888, 
DF = 41, P = NS) (Figure 2).
From baseline to t2, in both the NPPO-REAC and the ser-
traline groups, for fear (Figure 1) and avoidance (Figure 2), 
gSAD improved from marked to subthreshold for both fear 
and avoidance for NPPO-REAC.
Discussion and conclusion
This is probably the first study that compares the efficacy of 
a brain stimulation technique with a targeted drug, sertraline, 
in the treatment of gSAD. The results clearly demonstrate that 
NPPO-REAC treatment effectively and quickly reduces the 
core symptoms and the avoidance associated with this disor-
der. In this research, NPPO-REAC was globally statistically 
superior to standard dosages of sertraline on selected primary 
efficacy criteria, CGI improvement, and LSAS total score 
for fear and avoidance. Considering the early age at onset 
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and chronic course of this disorder, detecting a reduction 
in disability after only a 6-month follow-up is noteworthy. 
It is hoped, but remains to be shown in future studies, that 
longer duration and more cycles of NPPO-REAC treatment 
might result in even further structuration of results and, con-
sequently, in the reduction of functional impairment.
As previously demonstrated in the treatment of agora-
phobia, also in this study a sort of cognitive restructuration 
performed by NPPO-REAC has been highlighted, in order 
to guarantee the patient a more rational control of emotions 
when exposed to social and performance situations and, 
consequently, better management of the pattern of avoid-
ance behaviors.
In respect of the CGI scale, the greater percentage of 
patients who felt themselves to be much improved or very 
much improved with NPPO-REAC than with sertraline 
highlights the deeper action of the gentle NPPO-REAC brain 
stimulation compared with the drug.
Another aspect of particular interest is the feeling of natu-
ral and no artificial improvement of gSAD   symptomatology. 
This is very important, because typical of anxiety disorders, 
and probably one of the main reasons of the premature 
discontinuation of the drug treatment, is the feeling of the 
artificiality of the results. Therefore, from this point of view, 
the NPPO-REAC provides greater adherence to the treatment 
of these patients.
Obviously, there are a number of limitations to this study. 
SAD is a chronic and disabling disease that in any cases may 
require long-term therapy. Because of its design, this study 
did not accurately assess NPPO-REAC efficacy beyond the 
short, 6-month treatment period. It is possible, although not 
yet proven, that a longer course of therapy could result in 
sustained and even greater reductions in impairment and in 
improvement in quality of life.
Indeed, further studies of long-term treatment with 
NPPO-REAC are needed to determine the optimal duration 
of therapy, the number of NPPO-REAC cycles needed, and 
the efficacy in sustaining remission.
Because NPPO-REAC is also effective in the treatment 
of depressive symptoms, another limitation of this study is its 
inability to definitively demonstrate that reductions in social 
anxiety symptoms were not simply a secondary manifestation 
of this antidepressant effect.
Conclusion
NPPO-REAC is an effective treatment for SAD, allowing 
substantial and clinically meaningful reductions in symptoms 
and disability, in comparison with sertraline.
Disclosure
Salvatore Rinaldi and Vania Fontani are the inventors of the 
radio electric asymmetric conveyor.
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